XML 27 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Intangible Assets
 6 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
6.
Intangible Assets 
The reconciliation of intangible assets for the six months ended December 31, 2018 and for the years ended June 30, 2018 and 2017 was as follows (in thousands):
 
 
 
Six Months Ended
 
 
Year Ended
 
 
 
December 31,
 
 
June 30,
 
 
 
2018
 
 
2018
 
 
2017
 
Patented technologies
 
 
 
 
 
 
 
 
 
 
 
 
Gross carrying amount at beginning of period
 
$
68,322
 
 
$
35,610
 
 
$
36,196
 
Acquisition of Icon Bioscience Inc.
 
 
—
 
 
 
31,973
 
 
 
—
 
Foreign currency translation adjustments
 
 
—
 
 
 
739
 
 
 
(586
)
Gross carrying amount at end of period
 
 
68,322
 
 
 
68,322
 
 
 
35,610
 
Accumulated amortization at beginning of period
 
 
(36,964
)
 
 
(35,246
)
 
 
(35,094
)
Amortization expense
 
 
(1,229
)
 
 
(981
)
 
 
(724
)
Foreign currency translation adjustments
 
 
—
 
 
 
(737
)
 
 
572
 
Accumulated amortization at end of period
 
 
(38,193
)
 
 
(36,964
)
 
 
(35,246
)
Net book value at end of period
 
$
30,129
 
 
$
31,358
 
 
$
364
 
 
The net book value of the Company’s intangible assets at December 31, 2018, June 30, 2018
and June 30, 2017 is summarized as follows (in thousands):
 
 
 
 
 
 
 
 
 
 
 
 
Estimated
 
 
 
 
 
 
 
 
 
 
 
 
Remaining
 
 
 
 
 
 
 
 
 
 
 
 
Useful Life at
 
 
 
December 31,
 
 
June 30,
 
 
December 31,
 
 
 
2018
 
 
2018
 
 
2017
 
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
(Years)
 
Patented technologies
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEXYCU / Verisome
 
$
30,129
 
 
$
31,358
 
 
$
—
 
 
 
12.25
 
Durasert
 
 
—
 
 
 
—
 
 
 
265
 
 
 
—
 
Tethadur
 
 
—
 
 
 
—
 
 
 
99
 
 
 
—
 
 
 
$
30,129
 
 
$
31,358
 
 
$
364
 
 
 
 
 
The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization expense totaled $1.2 million in the six months ended December 31, 2018, $981,000 in fiscal 2018, $724,000 in fiscal 2017 and $756,000 in fiscal 2016, all of which amounts were included in research and development expense in the accompanying consolidated financial statements. Following the launch of DEXYCU, amortization expense will be included as a component of cost of sales.
In connection with the Icon Acquisition (see Note 3), the initial purchase price of $32.0 million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected useful life estimated to be 13 years at the rate of approximately $2.5 million per year.